Evidence map›Paper›PMID 16443885›Full record

Trial reportDiabetes care2006

Improving metabolic control leads to better working memory in adults with type 2 diabetes.

Christopher M Ryan, Martin I Freed, Julie A Rood, Alexander R Cobitz, Brian R Waterhouse, Mark W J Strachan

3 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 95 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 5 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04841668 completedstarted 2021, after this paper: background citation

Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly

Ran2021Enrolled50Registered outcomes51Posted comparisons0ConditionsType 2 Diabetes MellitusArmsMetformin
PMID 8013758PMID 30397356PMID 11118008PMID 18220635PMID 12086935PMID 28500216PMID 12930161PMID 16219009PMID 11602624PMID 28768369PMID 18806222PMID 18806780other papers from this trial
Open the trial in the graph
NCT03889132 completednot on this mapstarted 2019, after this paper: background citation

Integrated Analysis of the Interactions Between Glycemia and Microbiota Composition, and Their Impact on Brain Iron Deposition and Cognition in Subjects With Obesity

TypeobservationalSponsorInstitut d'Investigació Biomèdica de Girona Dr. Josep TruetaRan2019 to 2025Enrolled128ConditionsObesityArmsBariatric Surgery
NCT05345106 active not recruitingnot on this mapstarted 2022, after this paper: background citation

Inter-relationships Among Iron Stores, the Gut Metagenome, Glucose Levels, and Different Cognitive Domains: the Role of Circulating MicroRNAs (IRONmiRNA Study).

TypeobservationalSponsorInstitut d'Investigació Biomèdica de Girona Dr. Josep TruetaRan2022 to 2027Enrolled138ConditionsObesityArmsBariatric Surgery
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 5 syntheses or guidelines pooled it, 287 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. The impact of cognitive function on medication management: three studies.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2010
    Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Christopher M RyanUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. ryancm@upmc.edu
Martin I Freed
Julie A Rood
Alexander R Cobitz
Brian R Waterhouse
Mark W J Strachan
GlaxoSmithKline (United States) · USUniversity of Pittsburgh · USWestern General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe goals of this study were to determine whether improvements in metabolic control can ameliorate the cognitive dysfunction associated with type 2 diabetes and evaluate the possibility that such improvements are mediated by changes in circulating insulin or insulin resistance. RESEARCH DESIGN AND

methodsThis randomized double-blind trial enrolled 145 subjects at 18 centers in the U.S. Older adults with type 2 diabetes receiving metformin monotherapy received add-on therapy with either rosiglitazone, a thiazolidinedione insulin sensitizer, or glyburide. Cognitive function was assessed at baseline and week 24 using the Digit Symbol Substitution Test, the Rey Auditory Verbal Learning Test, and the Cambridge Neuropsychological Test Automated Battery.

resultsPretreatment fasting plasma glucose (FPG) in both groups was similar, and after 24 weeks both treatment groups showed similar significant reductions in FPG (2.1-2.3 mmol/l). Working memory improved with both rosiglitazone (P < 0.001) and glyburide (P = 0.017). Improvement (25-31% reduction in errors) was most evident on the Paired Associates Learning Test and was significantly correlated (r = 0.30) with improved glycemic control as measured by FPG.

conclusionsSimilar and statistically significant cognitive improvement was observed with both rosiglitazone and glyburide therapy, and the magnitude of this effect was correlated with the degree to which FPG improved. These results suggest that a cognitive benefit is achievable with pharmacological interventions targeting glycemic control.

Indexed as

AdultAgedBlood GlucoseCognitionDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleGlyburideHumansHypoglycemic AgentsMaleMemoryMetforminMiddle AgedPsychological TestsBlood GlucoseGlyburideHypoglycemic AgentsMetforminRosiglitazoneThiazolidinediones

Identifiers

PMID16443885
OpenAlexW2152471765

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.